Extensive-stage Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05509699 -
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05975944 -
Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04562337 -
A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00616109 -
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
|
Phase 2 | |
| Active, not recruiting |
NCT04373369 -
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04254471 -
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04774380 -
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT01555710 -
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
|
Phase 3 | |
| Completed |
NCT00682981 -
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04397003 -
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04487756 -
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03135977 -
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
|
Phase 2 | |
| Completed |
NCT03913455 -
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04663438 -
Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
|
||
| Not yet recruiting |
NCT03971214 -
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04101357 -
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
|
Phase 1/Phase 2 | |
| Completed |
NCT04636762 -
A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Not yet recruiting |
NCT04404543 -
A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT02323737 -
Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03911219 -
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy
|